文献速递主动脉疾病

使用Zenith开窗支架平台挽救失败或濒临失败的血管腔内及开放主动脉重建安全且技术可行

Use of the Zenith Fenestrated platform to rescue failing endovascular and open aortic reconstructions is safe and technically feasible.
PubMed 文献 · J Vasc Surg · 2018-05-18

该回顾性研究分析了2012年10月至2017年3月共103例使用Zenith开窗(ZFEN)平台行开窗血管腔内主动脉修复(FEVAR)的患者,其中12例为既往EVAR或开放手术后再次手术(rFEVAR)。rFEVAR组技术成功率100%与初次FEVAR组97.8%无差异,但透视时间、辐射暴露和手术时间显著增加;30天死亡率、主要不良心血管事件及再干预率无显著差异。作者结论认为,对特定患者,ZFEN用于挽救因疾病进展而失败或濒临失败的主动脉重建安全可行。

要点

  • rFEVAR组与初次FEVAR组技术成功率无显著差异(100% vs 97.8%,P=1.00)。
  • rFEVAR组透视时间、辐射暴露和手术时间较初次FEVAR组显著增加。
  • 两组30天死亡率、主要不良心血管事件及再干预率均无显著差异。

核心结论

  • 对特定患者,使用ZFEN平台行FEVAR挽救因疾病进展而失败或濒临失败的主动脉重建安全可行,不增加并发症率和死亡率。
  • 这些初步结果支持将ZFEN纳入主动脉再干预的治疗选择。

研究设计与样本

  • 回顾性综述前瞻性维护的机构数据库,纳入所有使用ZFEN平台行FEVAR的病例。
  • 共103例腹主动脉瘤患者因近端锚定区不足于2012年10月至2017年3月接受ZFEN治疗,其中12例为再次手术FEVAR(rFEVAR),包括既往EVAR 6例和开放手术6例。
  • 采用Fisher精确检验和Student t检验进行队列比较。

主要发现

  • rFEVAR指征包括开放手术后近端瘤颈扩张>55 mm(6例)、EVAR后IA型内漏(5例)及EVAR后近端瘤颈扩张无内漏(1例)。
  • 初次FEVAR与rFEVAR技术成功率无显著差异(97.8% vs 100%,P=1.00)。
  • rFEVAR组透视时间(61.1 vs 79.8分钟,P=0.04)、辐射暴露(415.9 vs 606.3 rad,P=0.02)和手术时间(228.4 vs 287.6分钟,P=0.03)较初次FEVAR组显著增加。
  • 两组估计失血量(363 vs 500 mL,P=0.25)和术中造影剂用量(97.3 vs 104.0 mL,P=0.55)无显著差异。
  • 30天围术期死亡率(2.2% vs 0%,P=1.0)、主要不良心血管事件(5.5% vs 0%,P=1.0)和支架相关不良事件(2.2% vs 0%,P=1.0)无显著差异;围术期再干预率(5.5% vs 0%,P=1.0)及平均随访20.8个月后的再干预率(18.6% vs 25.0%,P=0.70)亦无显著差异。

临床怎么用

  • 作者认为,对特定患者,ZFEN可用于因疾病进展而失败或濒临失败的主动脉重建的再干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Proximal neck dilation is a serious long-term complication directly causing the failure of endovascular aneurysm repair (EVAR) and open surgical repair (OSR) of abdominal aortic aneurysms. However, the implantation of a fenestrated device presents the opportunity for proximal extension of the aortic reconstruction into a healthy segment while maintaining patency of the visceral vessels. The objective of this investigation was to report perioperative and follow-up outcomes using the Zenith Fenestrated (ZFEN; Cook Medical, Bloomington, Ind) aortic stent system in salvaging previous aortic repairs undergoing type IA endoleak or aneurysmal degeneration of the proximal neck. METHODS: We performed a retrospective review of a prospectively maintained institutional database capturing all fenestrated EVAR (FEVAR) cases with the ZFEN platform. Fenestrated cases were classified as primary FEVAR or reoperative FEVAR (rFEVAR) after previous EVAR or OSR. Cohort comparisons were performed using Fisher exact tests and Student t-tests for categorical and continuous variables, respectively. RESULTS: Between October 2012 and March 2017, a total of 103 patients diagnosed with abdominal aortic aneurysm with an inadequate proximal seal zone for traditional EVAR were treated with ZFEN. In 12 patients, FEVAR was performed as a reoperation after previous EVAR (n = 6) or OSR (n = 6). The indications for rFEVAR were proximal neck dilation (>55 mm) after OSR (n = 6), type IA endoleak after EVAR (n = 5), and proximal neck dilation after EVAR without endoleak (n = 1). No difference in ability to achieve technical success was observed between primary FEVAR and rFEVAR (97.8% vs 100%; P = 1.00). In addition, there were no differences in estimated blood loss (363 vs 500 mL; P = .25) and intraoperative use of contrast material (97.3 vs 104.0 mL; P = .55). However, a significant increase in fluoroscopy time (61.1 vs 79.8 minutes; P = .04), radiation exposure (415.9 vs 606.3 rad; P = .02), and operative time (228.4 vs 287.6 minutes; P = .03) in the rFEVAR cohort was observed. In the 30-day perioperative period, there were no significant differences with regard to mortality (2.2% vs 0%; P = 1.0), major adverse cardiovascular events (5.5% vs 0%, P = 1.0), and stent-related adverse events (2.2% vs 0%; P = 1.0). There were no differences in rates of perioperative (5.5% vs 0%; P = 1.0) or follow-up reintervention after a mean follow-up duration of 20.8 months (18.6% vs 25.0%; P = .70). CONCLUSIONS: FEVAR with the ZFEN platform of failed and failing aortic reconstructions due to disease progression is safe and feasible without increased morbidity and mortality in select patients. These preliminary results support the inclusion of ZFEN as a treatment option for aortic reintervention.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang SK, Drucker NA, Sawchuk AP, et al. Use of the Zenith Fenestrated platform to rescue failing endovascular and open aortic reconstructions is safe and technically feasible. J Vasc Surg. 2018. PMID: 29784569. doi:10.1016/j.jvs.2018.01.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。